In the past decade, novel therapeutic agents such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and CD38‐targeting antibodies etc. have significantly improved MM prognosis, and the risk of severe RI in MM has also decreased [5]. This evidence concerns the gene CD38 and Miyoshi myopathy.